In vitro or ex vivo use of an amino acid sequence coded by nucleic acid sequence or nucleic acid sequence coding amino acid sequence, as a biomarker e.g. to identify active agents to prevent or treat impaired barrier function of scalp
In vitro or ex vivo use of at least one amino acid sequence coded by nucleic acid sequence having a SEQ ID NO: 1 (a 735 base pair sequence fully defined in the specification) or its analog or fragment, or of a nucleic acid sequence coding an amino acid sequence or its analog or fragment, as biomarker of impaired barrier function of a scalp, is claimed. Independent claims are included for: (1) a cosmetic use of the amino acid sequence, nucleic acid sequence or at least one inhibiting agent for the activity, expression or maturation of the amino acid sequence or the nucleic acid sequence, as active agent to prevent and/or treat impaired barrier function of the scalp, where the inhibiting agent comprises serpins, preferably lympho-epithelial Kazal-type-related inhibitor or serine protease inhibitor Kazal-type such as serine protease inhibitor Kazal-type-5 or serine protease inhibitor Kazal-type-6 or its fragment, sodium chloride, a combination of sodium chloride and sodium acetate, potassium chloride, ammonium, magnesium, calcium, glycosaminoglycan such as heparin, alpha -2-macroglobulin, calcium, potassium, ammonium, RNA interference, blocking antibody, aptamer, sodium citrate, sodium sulfate, magnesium ion and/or soybean trypsin inhibitor; (2) in vitro or ex vivo use of the amino acid sequence, the nucleic acid sequence or at least one activating agent for the activity, expression, maturation of the amino acid sequence or the nucleic acid sequence, for preparing reconstructed scalp model able to mimic impaired barrier function of the scalp, where the active agent comprises glycosaminoglycan such as heparin, heparin sulfate and/or dermatan sulfate; (3) in vitro or ex vivo process to characterize impaired barrier function of the scalp at an individual comprising performing, in an isolated scalp sample of the individual, a qualitative or quantitative measurement of the expression, activity or maturation of the amino acid sequence or the nucleic acid sequence, and comparing the obtained measurement with a reference measurement; (4) in vitro or ex vivo process for screening active or physical treatments capable of modulating the activity, expression or maturation of the amino acid sequence or the nucleic acid sequence, comprising disposing the amino acid sequence or the nucleic acid sequence in suitable conditions with the activity, expression or maturation of the sequences, contacting the amino acid sequence or the nucleic acid sequence with at least one active agent to test or expose the amino acid sequence or the nucleic acid sequence to a physical treatment to test, qualitatively or quantitatively measuring the activity, expression or maturation of the amino acid sequence or the nucleic acid sequence, and comparing the measurement with reference measurement; (5) in vitro or ex vivo process to characterize the effectiveness of the active agent or process to prevent and/or treat impaired barrier function of the scalp in the individual, comprising performing before the implementation of the active or process, in a first isolated scalp sample obtained from the individual, at least first qualitative or quantitative measurement of the activity, expression or maturation of the amino acid sequence or the nucleic acid sequence, performing, after the implementation of the active or process, in a second isolated scalp sample obtained from the individual, at least second measurement, qualitative or quantitative of the activity, expression or maturation of the amino acid sequence or the nucleic acid sequence, comparing the first and the second measurements to deduce of it information relating to the effect of implementation of the active or cosmetic method for preventing and/or treating impaired barrier function of the scalp; (6) a cosmetic process to prevent and/or treat impaired the barrier function of the scalp at an individual, comprising administering, to the individual, at least one composition comprising as active, at least one modulating agent of the activity, expression or maturation of the amino acid sequence or the nucleic acid sequence, where the modulating agent is an activating agent; (7) an isolated peptide having the amino acid sequence of SEQ ID NO: 8 (Leu-Val-His-Gly-Gly-Pro-Cys-Asp-Lys), SEQ ID NO: 9 (Lys-Pro-Asn-Leu-Gln-Val-Phe-Leu-Gly-Lys), SEQ ID NO: 10 (a 20 amino acid sequence fully defined in the specification) or SEQ ID NO: 11 (a 12 amino acid sequence fully defined in the specification) or their analog or fragment; (8) the composition comprising the peptide or nucleic acid sequence coding the peptide; and (9) an isolated reconstructed scalp model comprising at least one cell in which the expression, activity or maturation of the nucleic acid sequence having a SEQ ID NO: 1 or the amino acid sequence having a sequence of SEQ ID NO: 4 (a 244 amino acid sequence fully defined in the specification), or its fragment or analog, those is repressed or increased, where the isolated reconstructed scalp model is prepared using the process comprising contacting at least an effective quantity of the amino acid sequence, the nucleic acid sequence or the modulating agent with cells to generate isolated reconstructed scalp. ACTIVITY : Antiseborrheic; Dermatological; Antipsoriatic. MECHANISM OF ACTION : None given.
